Turning Point Brands replaces CEO Purdy as EBITDA outlook narrows

Turning Point Brands is in the middle of a rapid shift toward modern oral nicotine products, especially FRE and ALP white pouches, while legacy Zig-Zag products are weakening and the company is spending heavily to build distribution and brand awareness. Modern Oral represented 48% of Q2 net sales, while Zig-Zag sales declined year over year; management has been funding the transition with substantial investment and recently raised capital.

The leadership change is disruptive in timing but not a strategy reset. Graham Purdy leaves after more than two decades with TPB, effective September 30, and David Glazek becomes CEO on October 1. Glazek is an unusually familiar successor: he has been Executive Chairman since 2023 and a director since 2012. 〔0〕 That continuity reduces the likelihood of an immediate change to the white-pouch growth plan, but it also means the filing does not introduce a new operating catalyst or independent validation of execution.

The clearer business signal is the lower profit ceiling. TPB maintained its 2026 Modern Oral gross sales target at $330 million-$350 million and net sales target at $260 million-$270 million, but cut the top of its EBITDA range from $90 million to $80 million. The company is explicitly assuming that domestic manufacturing will not help margins until 2027 and that elevated freight costs will persist, so the growth story remains intact while near-term conversion of that growth into profit is weaker than previously framed.

Bottom line: TPB preserves its modern-oral growth targets and installs a well-known insider, but the CEO handoff arrives alongside a meaningful reduction in the profit range. The event is mixed: strategically continuous, financially less forgiving in the near term.